Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Immunotherapy Drugs Market Size to Reach Revenues of USD 326.36 Billion by 2026 - Arizton

This image opens in the lightbox

News provided by

Arizton Advisory & Intelligence

12 Oct, 2021, 17:00 GMT

Share this article

Share toX

Share this article

Share toX

CHICAGO, Oct. 12, 2021 /PRNewswire/ -- In-depth analysis and data-driven insights on the impact of COVID-19 included in this global immunotherapy drugs market report.

The immunotherapy drugs market is expected to grow at a CAGR of over 11.54% during the period 2020−2026.

Key Highlights Offered in the Report:  

  1. The monoclonal antibodies segment accounted for highest incremental growth about USD 116.68 billion, while the CAR-T cell therapy segment is likely to account for highest absolute growth rate of USD 1,279.79 billion during the forecast period. Over 5 CAR-T cell therapies approved during 2017-2020, with the global funding support.
  2. Kite Pharma, which is acquired by Gilead Sciences in 2017, received US FDA approval for Yescarta, which is the first CAR-T cell therapy. The drug generated a revenue of USD 70 million in the first quarter.
  3. North America in 2020 reported to have 56.28% share in immunotherapy market.
  4. The prevalence of cancer is on rise due to factors such as the adoption of westernization, increasing consumption of alcohol & smoking, etc. Hence, cancer segment is likely to witness the highest incremental growth of USD 126.48 billion by 2026.
  5. The approval of Kymriah for oncology treatment made Novartis AG the prominent vendor in immunotherapy market. The other key vendors are F. Hoffmann-La-Roche, Bristol-Myers Squibb, Merck & Co., Inc., GlaxoSmithKline, etc.

Key Offerings:

  • Market Size & Forecast by Revenue | 2020−2026
  • Market Dynamics – Leading trends, growth drivers, restraints, and investment opportunities
  • Market Segmentation – A detailed analysis by product, application, and geography
  • Competitive Landscape – 7 key vendors and 14 other vendors

Get your sample today! https://www.arizton.com/market-reports/immunotherapy-drugs-market-size-analysis 

Immunotherapy Drugs Market – Segmentation

  • In 2020, the monoclonal antibody segment accounted for a significant share of 72.6% in the global immunotherapy drugs market, which is expected to witness an incremental growth to reach USD 239.72 billion by the end of 2026.
  • Immune system modulators or immunomodulators are substances that support immune function by modifying (generally in a beneficial way) the immune system's response to a threat. The two types of immunomodulators include one that is restricted to a single antigen while the other is generalized. The immunomodulation obtained by a single antigen is known as specific immunomodulation.
  • In 2020, the autoimmune and inflammatory diseases segment accounted for a revenue share of 42.28%. Autoimmune diseases are triggered by abnormal immune responses to functional parts of the body. Immunotherapy has the potential to alter or rebalance the immune system, so it can be used to control autoimmune diseases.

Immunotherapy Drugs Market by Product

  • Monoclonal Antibodies
  • Immune System Modulators
  • Car T-Cell Therapies
  • Others

Immunotherapy Drugs Market by Application

  • Cancer
  • Auto Immune & Inflammatory Disease
  • Others

Immunotherapy Drugs Market – Dynamics

Immunotherapy, an unconventional biological treatment, has emerged as a prominent approach because it provides superior efficacy and safety. During the era of precision medicine and effective immunotherapies, the necessity for rapid and efficient antineoplastic development has never been greater. The untreated ailments have become treatable due to biologics. Compared to chemotherapy and radiation, immunotherapy is restricted to killing the cancer tissue by activating its system. The facility of immunotherapy lies in its specificity. These personalized medicines offer substantial clinical benefits, especially in patients who had little to no hope of survival a decade ago. Also, these therapies have significantly increased the survival rates for different types of cancers. Another prominent advantage of immune therapy relative to cancer medical treatments is the durability of responses.

Key Drivers and Trends fueling Market Growth:

  • Launch of Next-Generation Immunotherapies
  • COVID-19 as Growth Catalyst
  • Prevalence of Cancer & Autoimmune Diseases
  • Approval of Novel Immunotherapy Drugs

Immunotherapy Drugs Market – Geography

In 2020, North America accounted for a revenue share of 56.28% in the global immunotherapy drugs market. North America has the highest share among all the regions and is likely to witness an absolute growth of around 105% during the forecast period at a CAGR of 12.68%. In North America, cancers are the second most prominent reason for death after cardiovascular conditions among all age groups. The prevalence of cancers is high among the Hispanic, Asian American, and American Indian, and Alaskan Native populations in the region. The prevalence and effects of cancer vary significantly among racial and ethnic groups due to inequalities in wealth. Although the incidence of infection-associated cancers is low in the region, it is relatively higher for cancers associated with lifestyle-related risk factors.

Get your sample today! https://www.arizton.com/market-reports/immunotherapy-drugs-market-size-analysis 

Immunotherapy Drugs Market by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey

Major Vendors

  • F. Hoffmann-La Roche
  • Bristol Myers Squibb Company
  • Merck & Co., Inc.
  • GlaxoSmithKline
  • Novartis
  • AstraZeneca
  • Janssen Pharmaceuticals, Inc.

Other Prominent Vendors

  • AbbVie
  • Alexion Pharmaceuticals
  • Amgen
  • Bayer
  • Dendreon
  • Dynavax
  • Eli Lilly and Company
  • Elusys Therapeutics, Inc
  • Gilead Sciences, Inc
  • NBE Therapeutics
  • Pfizer, Inc
  • Sanofi
  • Seagen Inc.
  • Teva pharmaceuticals 

Explore our healthcare & lifesciences profile to know more about the industry.

Read some of the top-selling reports:

  • U.S. OTC Drugs Market - Industry Outlook & Forecast 2021-2026
  • Clinical Nutrition Market - Global Outlook and Forecast 2021-2026
  • U.S. In-Vitro Fertilization (IVF) Market - Industry Outlook and Forecast 2021-2026
  • Medical Tourism Market - Global Outlook & Forecast 2021-2026

About Arizton:

Arizton Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Mail: enquiry@arizton.com 
Call: +1-312-235-2040 
          +1 302 469 0707

Logo: https://mma.prnewswire.com/media/818553/Arizton_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.